https://cbu01.alicdn.com/img/ibank/2017/889/567/4015765988

https://cbu01.alicdn.com/img/ibank/2017/889/567/4015765988_996154267.220x220xz.jpg

author：Wikipedia 2025-09-30 00:46:07 - browse：81994

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Hollywood unions extend contract negotiations for actors
Next article： ASCO Daily Recap: CAR

WSS

Brain injuries and the importance of a second opinion

'Little Tech' descents on D.C., wanting a say in how AI is regulated

The health care issue Democrats can’t solve: hospital reform

Illumina board agrees to spin off Grail, as divestment plans proceed

Explaining an after

Illumina board agrees to spin off Grail, as divestment plans proceed

explore